Imatinib as a novel therapeutic approach for fibrotic disorders

被引：22

作者：

Distler, J. H. W. ^{[2
]}

Distler, O. ^{[1
]}

机构：

[1] Univ Zurich Hosp, Dept Rheumatol, CH-8091 Zurich, Switzerland

[2] Univ Erlangen Nurnberg, Dept Internal Med 3, Bavaria, Germany

来源：

RHEUMATOLOGY | 2009年 / 48卷 / 01期

关键词：

CHRONIC MYELOGENOUS LEUKEMIA; BONE-MARROW FIBROSIS; PULMONARY-FIBROSIS; SYSTEMIC-SCLEROSIS; TGF-BETA; MESYLATE; CARDIOTOXICITY;

D O I：

10.1093/rheumatology/ken431

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：2 / 4

页数：3

共 18 条

[1] Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis [J].

Abdollahi, A ;

Li, ML ;

Ping, G ;

Plathow, C ;

Domhan, S ;

Kiessling, F ;

Lee, LB ;

McMahon, G ;

Gröne, HJ ;

Lipson, KE ;

Huber, PE .

JOURNAL OF EXPERIMENTAL MEDICINE, 2005, 201 (06) :925-935

[2]

AKHMETSHINA A, 2008, FASEB J

[3]

AKHMETSHINA A, 2008, ARTHRITIS R IN PRESS

[4] Emerging safety issues with imatinib and other Abl tyrosine kinase inhibitors [J].

Atallah, Ehab ;

Kantarjian, Hagop ;

Cortes, Jorge .

CLINICAL LYMPHOMA & MYELOMA, 2007, 7 :S105-S112

[5] Treatment of chronic myelogenous leukemia with the tyrosine kinase inhibitor STI571 results in marked regression of bone marrow fibrosis [J].

Beham-Schmid, C ;

Apfelbeck, U ;

Sill, H ;

Tsybrovsky, O ;

Höfler, G ;

Haas, OA ;

Linkesch, W .

BLOOD, 2002, 99 (01) :381-383

[6] Imatinib mesylate therapy reduces bone marrow fibrosis in patients with chronic myelogenous leukemia [J].

Bueso-Ramos, CE ;

Cortes, J ;

Talpaz, M ;

O'Brien, S ;

Giles, F ;

Rios, MB ;

Medeiros, LJ ;

Kantarjian, H .

CANCER, 2004, 101 (02) :332-336

[7] Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis [J].

Daniels, CE ;

Wilkes, MC ;

Edens, M ;

Kottom, TJ ;

Murphy, SJ ;

Limper, AH ;

Leof, EB .

JOURNAL OF CLINICAL INVESTIGATION, 2004, 114 (09) :1308-1316

[8] Treatment of pulmonary fibrosis for twenty weeks with imatinib mesylate in a patient with mixed connective tissue disease [J].

Distler, Joerg H. W. ;

Manger, Bernhard ;

Spriewald, Bernd M. ;

Schett, Georg ;

Distler, Oliver .

ARTHRITIS AND RHEUMATISM, 2008, 58 (08) :2538-2542

[9] Cardiotoxicity of imatinib mesylate: an extremely rare phenomenon or a major side effect? [J].

Distler, Joerg H. W. ;

Distler, Oliver .

ANNALS OF THE RHEUMATIC DISEASES, 2007, 66 (06) :836-836

[10] Imatinib mesylate reduces production of extracellular matrix and prevents development of experimental dermal fibrosis [J].

Distler, Joerg H. W. ;

Juengel, Astrid ;

Huber, Lars C. ;

Schulze-Horsel, Ursula ;

Zwerina, Jochen ;

Gay, Renate E. ;

Michel, Beat A. ;

Hauser, Thomas ;

Schett, Georg ;

Gay, Steffen ;

Distler, Oliver .

ARTHRITIS AND RHEUMATISM, 2007, 56 (01) :311-322

← 1 2 →